Skip to main content

Make more Ebola drug and give it to Africans

By Harriet A. Washington
August 6, 2014 -- Updated 2021 GMT (0421 HKT)
STORY HIGHLIGHTS
  • Americans with Ebola received an experimental medicine that seemed to help
  • Harriet Washington: Poor Africans don't have access to lifesaving medicines
  • She says access to drugs often based on how much money you have and if you're a Westerner
  • She urges this drug be made in quantity and given to infected West Africans in a trial

Editor's note: Harriet A. Washington, a fellow at the Black Mountain Institute at the University of Nevada, Las Vegas, is the author of "Medical Apartheid: The Dark History of Experimentation from Colonial Times to the Present" and "Deadly Monopolies: The Shocking Corporate Takeover of Life Itself -- and the Consequences for Your Health and Our Medical Future." The opinions expressed in this commentary are solely those of the writer.

(CNN) -- One of the many questions surrounding the revelation that Americans Kent Brantly and Nancy Writebol received a little-known, experimental serum for their Ebola infection is: "Why did we hear nothing about it earlier, and how did they gain access to it?"

Ebola has no cure, although potential medications and vaccines are in various states of development. The serum ZMapp, an experimental product of Mapp Biopharmaceutical, hasn't been tested in humans, which means it doesn't meet a primary requirement for FDA approval -- so its obscurity is no surprise.

The Americans managed to gain access to what more than 1,660 infected people in Guinea, Sierra Leone, Liberia and now Nigeria did not: medicine that seems to work -- although, of course, we don't know for sure yet. Some reports indicate they received ZMapp under the FDA's "compassionate use" rule, which permits untested drugs to be given to consenting patients who might otherwise die. This is a triumph of common sense and compassion over bureaucratic red tape.

Harriet A. Washington
Harriet A. Washington

One of the chief concerns about using unapproved medications is that we don't know what the risks are: The drug may not work, it may work with serious adverse effects, or it may prove as deadly as the disease. But as a doctor, Brantly understood the risks, and like him, Writebol had no other options. Most people with Ebola die.

Compassionate use is certainly ethically defensible. But apparently only three doses were available, and they were given to Westerners. The lack of broader access to ZMapp highlights what is often a very serious ethical failing.

9 questions about this new Ebola drug

Christine Wade, a registered nurse at the University of Texas Medical Branch, greets Carnival Magic passengers disembarking in Galveston, Texas, on Sunday, October 19. Nurses met passengers with Ebola virus fact sheets and to answer any questions. A Dallas health care worker was in voluntary isolation, although she had shown no signs of the disease, in her cabin aboard the cruise ship because of her potential contact with the Ebola virus. Christine Wade, a registered nurse at the University of Texas Medical Branch, greets Carnival Magic passengers disembarking in Galveston, Texas, on Sunday, October 19. Nurses met passengers with Ebola virus fact sheets and to answer any questions. A Dallas health care worker was in voluntary isolation, although she had shown no signs of the disease, in her cabin aboard the cruise ship because of her potential contact with the Ebola virus.
The Ebola epidemic
HIDE CAPTION
<<
<
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
>
>>
Photos: The Ebola epidemic Photos: The Ebola epidemic

Why didn't Dr. Sheik Umar Khan, the chief Sierra Leone physician who died while treating Ebola patients, receive this medication? Because another method of determining who gets medications is at work here -- the drearily familiar stratification of access to a drug based on economic resources and being a Westerner rather than a resident of the global South.

Ebola vaccine delayed for business reasons?
How the experimental Ebola serum works
Fight against Ebola given new momentum

No health worker wants to intentionally deprive Africans of a needed drug. But informal medical networks, which Africans lack, connect well-to-do Westerners with information and drugs. In addition, the pharmaceutical industry has a history of declining to test medications for diseases of the tropical world, most of whose inhabitants cannot afford high prices.

We don't know how quickly ZMapp could be made in large quantities. If it were to be made available, who should receive it? Some think Ebola doctors and caregivers should, because their survival is essential to treating and quelling the epidemic. This makes sense, but it's not that simple.

First, it violates the principle of distributive justice: The benefits of the drug are being inequitably distributed, with skilled, economically secure professionals more likely to benefit.

Also, by what reckoning do we decide that the doctors' role increases their value and dictates they should be given a preferential chance to survive? Distributing the drug through a clinical trial would allow us to know whether and how well the medication works and what caveats might apply.

Africans must participate in any clinical trial, which would benefit the pharmaceutical company as well as, it's hoped, Ebola victims. This would mean their lives have irreplaceable value, too, in the equation of who should get the drug.

So, will Africans receive this potentially lifesaving medication?

A U.N. official suggested that drugs cannot be tested in the middle of an epidemic -- but he is wrong. Such tests are conducted all the time.

Dr. David Ho tested AIDS drugs in Uganda in the midst of the pandemic, and the meningitis drug Trovan was tested in Kano, Nigeria, in the midst of an epidemic. One of every three industry trials is conducted in developing countries; scientists often point to high disease rates, including epidemics, as a rationale for conducting them there.

The problem is not testing the drug amid an epidemic. The question is how ethically such trials are conducted.

Only small amounts of ZMapp are available now, but as soon as it can be made in quantity, the drug for Ebola should be made available to Africans in all the regions that are threatened by the epidemic, regardless of ability to pay.

If possible, it should be distributed within clinical trials to determine the safety and efficiency of the medications. Many people assume this requires withholding medications in a control group, but this is not necessarily the case. Experts should and can mount a well-designed study that permits early access to the medication to all who need it.

But if they cannot ensure that sick people get the drug early, then a clinical trial should not be any more of a requirement for poor Africans than it was for Kent Brantly.

It's also natural to wonder whether the threat of Ebola to the Western world, not to Africans, drives this initiative because so few such drugs are devised for Africans.

This simply highlights another reason why we should so our utmost to protect people from Ebola: our medical interdependence. If Ebola makes landfall in the United States, we will need drugs like ZMapp, just as Africans need them today.

Read CNNOpinion's new Flipboard magazine.

Follow us on Twitter @CNNOpinion.

Join us on Facebook.com/CNNOpinion.

Part of complete coverage on
October 17, 2014 -- Updated 2334 GMT (0734 HKT)
The world's response to Ebola is its own sort of tragedy, writes John Sutter
October 17, 2014 -- Updated 2033 GMT (0433 HKT)
Hidden away in Russian orphanages are thousands of children with disabilities who aren't orphans, whose harmful treatment has long been hidden from public view, writes Andrea Mazzarino
October 18, 2014 -- Updated 1722 GMT (0122 HKT)
When you hear "trick or treat" this year, think "nudge," writes John Bare
October 18, 2014 -- Updated 0442 GMT (1242 HKT)
The more than 200 kidnapped Nigerian schoolgirls have become pawns in a larger drama, writes Richard Joseph.
October 17, 2014 -- Updated 1345 GMT (2145 HKT)
Peggy Drexler said Amal Alamuddin was accused of buying into the patriarchy when she changed her name to Clooney. But that was her choice.
October 16, 2014 -- Updated 2043 GMT (0443 HKT)
Ford Vox says the CDC's Thomas Frieden is a good man with a stellar resume who has shown he lacks the unique talents and vision needed to confront the Ebola crisis
October 18, 2014 -- Updated 0858 GMT (1658 HKT)
How can such a numerically small force as ISIS take control of vast swathes of Syria and Iraq?
October 17, 2014 -- Updated 1342 GMT (2142 HKT)
How big a threat do foreign fighters in Syria and Iraq pose to the West? It's a question that has been much on the mind of policymakers and commentators.
October 17, 2014 -- Updated 1221 GMT (2021 HKT)
More than a quarter-million American women served honorably in the Iraq and Afghanistan wars. Now they are home, we have an obligation to help them transition back to civilian life.
October 16, 2014 -- Updated 2027 GMT (0427 HKT)
Paul Begala says Rick Scott's deeply weird refusal to begin a debate because rival Charlie Crist had a fan under his podium spells disaster for the Florida governor--delighting Crist
October 16, 2014 -- Updated 0407 GMT (1207 HKT)
The longer we wait to engage on Ebola, the more limited our options will become, says Marco Rubio.
October 15, 2014 -- Updated 1153 GMT (1953 HKT)
Democratic candidates who run from President Obama in red states where he is unpopular are making a big mistake, says Donna Brazile
October 16, 2014 -- Updated 0429 GMT (1229 HKT)
At some 7 billion people, the world can sometimes seem like a crowded place. But if the latest estimates are to be believed, then in less than a century it is going to feel even more so -- about 50% more crowded, says Evan Fraser
October 16, 2014 -- Updated 1938 GMT (0338 HKT)
Paul Callan says the Ebola situation is pointing up the need for better leadership
October 15, 2014 -- Updated 2245 GMT (0645 HKT)
Nurses are the unsung heroes of the Ebola outbreak. Yet, there are troubling signs we're failing them, says John Sutter
October 15, 2014 -- Updated 1700 GMT (0100 HKT)
Dean Obeidallah says it's a mistake to give up a business name you've invested energy in, just because of a new terrorist group
October 15, 2014 -- Updated 2301 GMT (0701 HKT)
Fear of Ebola is contagious, writes Mel Robbins; but it's time to put the disease in perspective
October 14, 2014 -- Updated 1744 GMT (0144 HKT)
Oliver Kershaw says that if Big Tobacco is given monopoly of e-cigarette products, public health will suffer.
October 18, 2014 -- Updated 1335 GMT (2135 HKT)
Stop thinking your job will make you happy.
October 15, 2014 -- Updated 0208 GMT (1008 HKT)
Ruben Navarrette says it's time to deal with another scandal involving the Secret Service — one that leads directly into the White House.
October 14, 2014 -- Updated 1125 GMT (1925 HKT)
Americans who choose to fight for militant groups or support them are young and likely to be active in jihadist social media, says Peter Bergen
October 13, 2014 -- Updated 1303 GMT (2103 HKT)
Stephanie Coontz says 11 years ago only one state allowed same sex marriage. Soon, some 60% of Americans will live where gays can marry. How did attitudes change so quickly?
October 14, 2014 -- Updated 2004 GMT (0404 HKT)
Legalizing assisted suicide seems acceptable when focusing on individuals. But such laws would put many at risk of immense harm, writes Marilyn Golden.
October 13, 2014 -- Updated 1307 GMT (2107 HKT)
Julian Zelizer says the issues are huge, but both parties are wrestling with problems that alienate voters
October 13, 2014 -- Updated 2250 GMT (0650 HKT)
Mel Robbins says the town's school chief was right to cancel the season, but that's just the beginning of what needs to be done
October 11, 2014 -- Updated 1543 GMT (2343 HKT)
He didn't discover that the world was round, David Perry writes. So what did he do?
ADVERTISEMENT